These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18684702)

  • 21. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
    Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
    Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 24. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
    Wilcox MH
    J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tigecycline: an antibiotic for the twenty-first century.
    Dryden M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of an interaction between tigecycline and digoxin in healthy men.
    Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
    Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic challenges in the era of antibiotic resistance.
    Lee C
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.
    Falagas ME; Metaxas EI
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):913-23. PubMed ID: 19803699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
    Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
    Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
    Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
    Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
    Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
    Nikitin AV
    Antibiot Khimioter; 2009; 54(1-2):63-6. PubMed ID: 19499721
    [No Abstract]   [Full Text] [Related]  

  • 37. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 38. Tigecycline: a novel broad-spectrum antimicrobial.
    Slover CM; Rodvold KA; Danziger LH
    Ann Pharmacother; 2007 Jun; 41(6):965-72. PubMed ID: 17519296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
    Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.